Table 1.
Serial Clinical and Serum Markers Captured During Extreme Endurance Event With Comparison to Healthy Control Cohort
| Healthy Cohort (n = 15) | Subject |
||||
|---|---|---|---|---|---|
| Baseline (−2 Months) | Prerun (−2 Days) | Peak Run (11 Days) | Convalescence (+2 Months) | ||
| Clinical characteristics | |||||
| Age, y | 44.4 ± 14.6 | 37 | |||
| Male | 9 (60) | 1 (100) | |||
| Height, m | 1.74 ± 0.08 | 1.78 | |||
| Weight, kg | 75.8 ± 13.1 | 74.0 | 70.3 | 70.0 | 72.0 |
| BSA, kg/m2 | 1.91 ± 0.20 | 1.91 | 1.86 | 1.87 | 1.9 |
| Systolic blood pressure, mm Hg | 111.1 ± 12.3 | 104 | 114 | 114 | 107 |
| Diastolic blood pressure, mm Hg | 69.8 ± 9.2 | 51 | 61 | 61 | 51 |
| Heart rate, beats/min | 57.8 ± 11.2 | 51 | 58 | 74 | 67 |
| Hypertension | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Hyperlipidemia | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Diabetes | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Serum biomarkers | |||||
| Troponin T, ng/L | 5.0 ± 4.1 | 3 | 4 | 37 | 3 |
| NT-proBNP, pg/mL | 29.2 ± 28.3 | 25 | 85 | 782 | 25 |
| LDL cholesterol, mmol/L | 2.59 ± 0.84 | 2.97 | 2.97 | 1.38 | 2.28 |
| HDL cholesterol, mmol/L | 1.45 ± 0.45 | 2.21 | 2.21 | 1.66 | 1.56 |
| Triglycerides, mmol/L | 1.74 ± 1.48 | 1.11 | 1.11 | 1.37 | 1.86 |
| Creatinine, mmol/L | 84.1 ± 13.2 | 96 | 96 | 98 | 80 |
| Hemoglobin, mg/dL | 146.4 ± 8.3 | 160 | 160 | 131 | 148 |
| Hematocrit, % | 43.3 ± 2.1 | 47 | 47 | 39 | 43 |
Values are mean ± SD, n, or n (%). As a descriptive study of serial evaluations performed in a single subject no additional statistical analyses were required nor appropriate to perform. Peak endurance activity serum biomarker measurements represented in bold.
BSA = body surface area; HDL = high-density lipoprotein; LDL = low-density lipoprotein; NT-proBNP = N-terminal pro–B-type natriuretic peptide.